123). It is noteworthy that GLS2 is tumorigenic in breast cancer124, and its expression could compensate for lack of Gls in MYC-induced mouse liver tumours40. This suggests that GLS2 could confer resistance to GLS1-specific inhibitors, like the allosteric inhibitor BPTES or CB-839, which resistance

Therapy with SR18662 significantly lowers growth and proliferation of CRC cells. SR18662 displays enhanced efficacy in cutting down viability of a number of CRC cell strains. Flow cytometry Assessment pursuing SR18662 remedy reveals a rise in cells captured in both S or G2/M phases from the mobile c